Gapping up
In reaction to strong earnings/guidance:
- SDRL +6.2%, AQUA +5.4%, STNE +3.2%, MTSC +2.8%, ENTA +2.2%, UNH +1%, CAAP +1%
M&A news:
- ADS +0.5% (exploring strategic alternatives for Epsilon business)
Other news:
- ABEO +11.9% ( announces immediate termination of CEO Dr. Carsten Thiel due to "personal misconduct"; appoints Chief Medical Officer Dr. João Siffert as Interim CEO)
- SAVE +10.8% (sees Q4 TRASM +11% y/y and modestly improved Q4 range for CASM ex fuel)
- MXIM +4.7% (to join S&P 500)
- LOXO +3.4% (receives FDA approval for Vitrakvi)
- FANG +2.9% (to join S&P 500)
- PCG +1.5% (extending today's move higher)
- RCKT +1.5% (FDA has granted Regenerative Medicine Advanced Therapy and Fast Track designations to RP-L102; announces public offering of $50 mln of shares of its common stock)
- ZYME +0.8% (Zymeworks and BeiGene (BGNE) enter strategic collaboration for the clinical development and commercialization of Zymeworks' investigational ZW25 and ZW49 HER2-targeted bispecific antibodies)
- MRK +0.7% (ticking higher on BMY Phase 3 CheckMate -451 Opdivo study results)
- MNK +0.7% (following Citron related decline)
- UTX +0.6% (United Tech to separate into three independent companies and updates outlook to reflect completion of its acquisition of Rockwell Collins)